Who Is Watching the Medicines? Why UK Care Homes Need Stronger Clinical Oversight

Healthcare assistants play an essential role in administering medicines in residential care. But safe administration is not the same as clinical oversight. Unless the system ensures that residents’ medicines are regularly reviewed, interactions are identified, adverse effects are investigated and professional advice is readily available, preventable harm can go unnoticed.

The distinction that matters

In care homes across the UK, medicines are frequently administered by healthcare assistants and other care staff who are not registered healthcare professionals. This arrangement is not inherently unsafe or inappropriate. Staff who have received suitable training, been assessed as competent and are working within clear procedures can administer prescribed medicines safely and effectively.

The problem arises when the delegation of administration is not matched by effective clinical oversight.

Giving a tablet according to a medication administration record is a different task from determining whether that tablet remains appropriate for a particular resident, whether it interacts with other prescribed medicines, or whether the resident is experiencing an adverse reaction. These activities require different knowledge, skills and professional responsibilities.

The fundamental question is not who physically gives the medicine, but who takes responsibility for ensuring that the complete medication regimen remains clinically appropriate and safe.

In a care system where GPs prescribe, pharmacies dispense and care assistants administer, responsibility can become fragmented. Each participant may perform their assigned task, yet gaps can remain between prescribing decisions, the administration of medicines, clinical monitoring and subsequent review.

For residents who are frail, living with dementia or taking multiple medicines, those gaps matter. They can mean that a harmful combination persists, a side effect goes unrecognised or an unnecessary medicine continues long after its original purpose has disappeared.

The answer is not to diminish the role of care assistants or insist that every routine dose must be administered by a nurse. It is to establish a system in which delegated administration is supported by clear accountability, accessible clinical expertise and reliable review of the resident’s treatment.

The evidence of medication errors

The risks associated with medicines management in care homes have been documented in published research for many years.

In 2009, Barber and colleagues published the Care Homes’ Use of Medicines Study (CHUMS), investigating medication errors among residents in UK care homes. The study examined 256 residents across 55 homes and found that 178 residents, or 69.5% of the sample, had experienced at least one medication error. Residents were taking an average of eight medicines.

The researchers identified contributing factors that included staff workload, interruptions during medication rounds, inadequate training, inaccurate records and communication failures between care homes, GP practices and pharmacies. They also highlighted weaknesses in overall responsibility for medicines safety.

These findings are important because they point beyond individual mistakes. A medication error may occur at the point of administration, but its underlying causes can lie elsewhere: an inaccurate prescription, a failure to communicate a change in treatment, inadequate monitoring or the absence of an effective process for reviewing the whole medication regimen.

Barber et al., Care Homes’ Use of Medicines Study, Quality and Safety in Health Care, 2009.

The figures must be interpreted in their historical context. They describe the residents and homes studied in 2009 and should not be presented as an estimate of the current national error rate. Nevertheless, the study remains an important examination of the organisational weaknesses that can undermine medicines safety.

A 2022 review published in The Pharmaceutical Journal, examining medication errors and inappropriate medicine use in UK care homes, also identified prescribing and administration errors as significant concerns. The literature discussed factors including polypharmacy, understaffing, dementia, swallowing difficulties and inadequate communication between prescribers, pharmacists and care staff. The authors highlighted the potential value of regular pharmacist-led medication reviews, staff education and improved reporting of medication errors.

Pepple and Boumechache, Errors and the inappropriate use of medicines in UK care homes, 2022.

Taken together, these publications support a clear conclusion: medicines safety depends on the reliability of the whole system, not simply on whether the person administering a dose follows the correct procedure.

Why correct administration does not guarantee safe treatment

Imagine a resident receiving medicines for hypertension, heart disease, diabetes, chronic pain and anxiety. Each medicine may have been prescribed for a legitimate reason. The resident’s care assistant administers each dose correctly and records it accurately.

Yet the resident begins to experience dizziness, increasing confusion and recurrent falls.

The administration records may reveal no error. The medicines may have been given at the prescribed times and in the prescribed doses. Nevertheless, the combined treatment may be contributing to the resident’s deterioration.

Several medicines can have additive effects on blood pressure, alertness or balance. Changes in kidney function can affect the handling of particular drugs. An illness, an episode of dehydration or a hospital admission can alter the balance between the benefits and risks of an established regimen. A medicine that was once appropriate may become unnecessary or harmful as the resident’s condition changes.

A care assistant may be the first person to notice that the resident is unusually drowsy or unsteady. That observation is clinically valuable and should trigger an appropriate response. But determining whether the symptoms represent an adverse drug reaction, an interaction, an excessive cumulative effect or an unrelated illness requires further assessment.

This is where the distinction between administration and oversight becomes critical.

Care assistants should not be expected to diagnose complex drug interactions or independently alter prescriptions. Equally, a system should not depend on them recognising every potential interaction or adverse effect before a qualified professional becomes involved.

Their responsibility is to administer medicines within their competence, observe the resident, document relevant information and escalate concerns. The clinical system must then ensure that those concerns can be assessed promptly and that treatment can be reconsidered when necessary.

Without this link, even a perfectly completed medication administration record can coexist with unsafe treatment.

Polypharmacy requires active clinical management

Polypharmacy is common among older people and is not automatically inappropriate. For residents with several chronic conditions, multiple medicines may be necessary to manage symptoms, prevent complications and maintain quality of life.

The problem is inappropriate or insufficiently reviewed polypharmacy: combinations that no longer provide sufficient benefit, create avoidable risks or continue without adequate consideration of the resident’s changing circumstances.

Potential concerns include:

1. Interactions that increase the toxicity of one or more medicines.
2. Combined sedative effects that contribute to falls, impaired alertness or confusion.
3. Multiple medicines contributing to low blood pressure or an increased risk of bleeding.
4. Adverse effects being mistaken for the progression of dementia or another underlying illness.
5. Medicines continuing after their original indication has disappeared.
6. A new medicine being prescribed to treat a symptom caused by another medicine, creating a prescribing cascade.

Identifying these problems requires more than checking the individual entries on a medication administration record. It requires consideration of the resident’s complete treatment, medical history, current symptoms, relevant investigations and personal priorities.

The Royal Pharmaceutical Society’s report, The Right Medicine: Improving Care in Care Homes (2016), provides a professional basis for strengthening this approach. It advocates a greater role for pharmacists in improving medicines management and working with care homes and other healthcare professionals.

Royal Pharmaceutical Society, The Right Medicine: Improving Care in Care Homes.

The significance of this approach is that clinical oversight should examine the whole regimen, rather than treating each prescription as an isolated decision. It should also establish whether intended benefits are being achieved, whether adverse effects are emerging and whether any medicines can be reduced or discontinued safely.

The guidance exists. The challenge is making it effective.

The National Institute for Health and Care Excellence (NICE) published Managing medicines in care homes (SC1) in 2014. Its recommendations address medicines-related responsibilities, staff competence, record keeping, medication errors, communication and medication reviews.

NICE expects care home providers to ensure that staff administering medicines are suitably trained and assessed as competent. It also recommends arrangements for medication reviews, including the involvement of a named health professional with appropriate clinical experience and knowledge of the resident. Reviews should take account of the resident’s needs and preferences and involve other professionals when appropriate.

Source: NICE, Managing medicines in care homes, recommendations.

These recommendations support the distinction at the heart of this article. Care staff can undertake the practical task of administering medicines, but this must operate within a wider framework of professional review, monitoring and accountability.

The existence of guidance does not establish that all homes follow it effectively. Nor does it prove that every home without an on-site registered nurse is unsafe. The relevant issue is whether each resident has access to appropriate clinical oversight, whether responsibilities are clearly assigned and whether the system responds effectively when risks emerge.

A written medicines policy is not enough if staff cannot obtain timely advice. A completed training record is not enough if nobody reviews the consequences of a complex medication regimen. A periodic medication review is not enough if significant changes in a resident’s condition are not recognised and acted upon between reviews.

The test should be whether the arrangements work in practice.

Why periodic reviews must be supported by ongoing oversight

Scheduled medication reviews are important, but they cannot anticipate every change in a resident’s health.

A hospital discharge may introduce new medicines, discontinue existing treatments or alter doses. An acute illness may affect kidney function, hydration or the resident’s ability to swallow. A new symptom may indicate an adverse reaction. A fall or a sudden change in mental state may require an urgent reassessment of treatment.

Care staff are often best placed to observe these changes because they provide day-to-day support. Their observations should feed into a clear clinical escalation process.

This does not mean that a doctor or pharmacist must be physically present whenever medicines are administered. Nor does it mean that every dose requires fresh clinical authorisation. It means that suitably qualified professionals must be responsible for reviewing treatment, be able to access relevant information and be available to advise when circumstances require reassessment.

NHS England’s structured medication review programme identifies care home residents as a group for whom structured reviews may be particularly important. The purpose is to consider the benefits and risks of treatment, particularly in people with complex or problematic polypharmacy.

NHS England, Structured medication reviews and medicines optimisation.

The policy direction is clear: medicines should be reviewed in the context of the individual resident, rather than continued indefinitely simply because they remain on a repeat prescription.

What is needed is a dependable connection between these reviews and everyday care. Staff must know how to report concerns, who will assess them and how resulting decisions will be communicated and implemented.

A model that separates responsibilities but joins up care

A safer approach would preserve the contribution of healthcare assistants while strengthening the clinical systems that support them.

1. Clear responsibility for the complete medication regimen

Every resident should have an identifiable arrangement for clinical medication review. Depending on the resident’s needs and local services, this may involve a suitably qualified pharmacist, GP or other appropriately trained prescriber.

The important requirement is that responsibilities are explicit, relevant information is available and someone has the authority and competence to assess the complete regimen.

Naming a professional on a care plan is not sufficient if that person cannot obtain the information needed to conduct a review or if recommendations are not followed through.

2. Comprehensive, risk-based medication reviews

Reviews should consider the indication for each medicine, potential interactions, cumulative side effects, relevant monitoring, the resident’s response to treatment and the possibility of reducing unnecessary medication.

They should also take account of the resident’s wishes and priorities. The objective is not to minimise the number of medicines at any cost, but to achieve the best balance of benefit and harm for the individual.

3. Timely clinical advice when concerns arise

Care staff need clear instructions on what to do when a resident develops new symptoms, refuses medicines, experiences a fall or shows a significant change in their condition.

There must be an effective route to professional assessment, with urgent concerns escalated appropriately. Where a medication discrepancy or possible adverse reaction is identified, staff need to know whom to contact and how the outcome will be recorded.

4. Training appropriate to the responsibilities of care staff

Training should cover safe administration, accurate documentation, the importance of following the current prescription and the recognition of warning signs. Staff should know the limits of their role and be confident about reporting concerns without being expected to make clinical decisions outside their competence.

Competence assessments and refresher training are necessary, but training should complement rather than substitute for professional oversight.

5. Monitoring and learning from medication incidents

Providers and their clinical partners should monitor errors, omissions, discrepancies, adverse reactions and delays in medication review. Near misses should also be reported and examined.

When incidents occur, investigations should consider not only the actions of the person administering the medicine but also the prescribing process, communication between organisations, staffing conditions, access to clinical advice and the adequacy of monitoring.

The objective should be to correct weaknesses in the system rather than reflexively attributing every failure to an individual member of staff.

6. Properly resourced clinical involvement

Pharmacist input, GP support and nursing expertise require time, agreed responsibilities and effective communication. Providers and commissioners must make suitable arrangements rather than relying on informal assistance or the goodwill of already overstretched professionals.

The appropriate level of involvement will vary with residents’ needs and the complexity of their treatment. However, the need for clinical oversight should not depend on whether a home happens to have a registered nurse permanently on site.

These changes would not remove all medication errors. They would, however, address the organisational conditions that can allow prescribing problems, adverse effects and medication discrepancies to persist undetected.

Accountability must extend beyond the person administering the medicine

When a medication error occurs, the most visible event may be an incorrect dose, an omitted tablet or a missing signature on a medication administration record.

Those matters require investigation. But a complete investigation must also ask whether the prescription was appropriate, whether the records were accurate, whether changes in treatment were communicated, whether monitoring was undertaken and whether staff could obtain clinical advice when necessary.

A care assistant may be responsible for following the procedures and instructions applicable to their role. They should not, however, become the default point of accountability for weaknesses that originate elsewhere in the system.

Responsibility must follow professional roles and actual control over decisions.

Prescribers are responsible for their prescribing decisions. Pharmacists contribute medicines expertise. Registered nurses, where involved, have responsibilities appropriate to their roles. Care assistants must work within their competence and report concerns. Care providers must maintain safe systems and ensure staff have the necessary training, information and support. Commissioners and healthcare services must establish workable arrangements for clinical input.

The Care Quality Commission’s medicines-management guidance reinforces the importance of safe systems for prescribing, handling and administering medicines.

CQC, guidance on medicines management and learning from safety incidents.

The central principle is straightforward: a system should not rely on every individual performing their task perfectly to compensate for gaps in the organisation of care. It should include safeguards that can identify problems, escalate concerns and correct mistakes before they cause harm.

The resident must remain at the centre

Medication safety is not simply a matter of compliance with procedures. It is about protecting people whose health, independence and quality of life may be profoundly affected by the medicines they receive.

A resident living with dementia may be unable to describe dizziness, nausea or increasing confusion. Someone with swallowing difficulties may struggle to take medicines as prescribed. A frail resident taking several medicines may be unable to recognise that increasing tiredness or unsteadiness could be treatment-related.

These people depend on care staff to notice changes and on clinical professionals to interpret those observations and act appropriately.

They also deserve to be involved in decisions about their treatment to the extent that they are able, with appropriate support where needed. A medication review should not be a purely administrative exercise between professionals. It should consider what matters to the resident, which symptoms are troubling them and whether the treatment continues to serve their interests.

Effective oversight therefore protects not only against medication errors but also against unnecessary treatment, avoidable side effects and the continuation of medicines that no longer provide sufficient benefit.

Conclusion: strengthen oversight, not blame care assistants

The evidence from UK care home research, together with guidance from NICE, the Royal Pharmaceutical Society and NHS England, supports the need for better-organised medicines management, clear professional responsibilities and structured clinical review.

The solution is not to prohibit appropriately trained healthcare assistants from administering medicines. Delegated administration can be a legitimate and effective part of residential care. The solution is to ensure that delegation never becomes a substitute for clinical oversight.

Administering a medicine correctly does not establish that the medicine is appropriate, that its combination with other treatments is safe or that its effects are being monitored adequately.

Every care home should be able to explain who is responsible for reviewing each resident’s medication regimen, how potentially harmful interactions and adverse effects are identified, how changes in the resident’s condition trigger reassessment and how quickly qualified clinical advice can be obtained.

It should also be possible to demonstrate that medication reviews lead to action, that incidents are investigated and that recurring problems result in improvements to the system.

If these safeguards are absent or ineffective, the problem is not simply a lack of individual training. It is a failure to connect the administration of medicines with the clinical expertise required to manage their risks.

Healthcare assistants should be supported to carry out their responsibilities safely and confidently. Residents, meanwhile, should be entitled to expect that the medicines they receive are not only administered correctly but also prescribed appropriately, reviewed regularly and monitored with the seriousness their health requires.

The objective must be a system in which responsibility for administering medicines is delegated appropriately, but responsibility for clinical oversight is never left ambiguous.

Principal references

1. Barber, N. et al. (2009). Care Homes’ Use of Medicines Study (CHUMS). Full paper .
2. Pepple and Boumechache (2022). Errors and the inappropriate use of medicinesin UK care homes. The Pharmaceutical Journal .
3. Royal Pharmaceutical Society (2016). The Right Medicine: Improving Carein Care Homes. Report .
4. NICE (2014). Managing medicines in care homes (SC1). Recommendations .
5. NHS England. Structured medication reviews and medicines optimisation. Programme guidance .
6. Care Quality Commission. Medicines management: learning from safetyincidents. Guidance .

Editorial note: The article is framed primarily around England because the cited NICE and CQC guidance applies there. Before publication as a UK-wide policy critique, the regulatory position and equivalent guidance in Scotland, Wales and Northern Ireland should be checked separately. The research statistics are attributed to the original studies rather than presented as current national estimates.